Standard Treatment for PKU
Sapropterin (Kuvan) treats PKU by boosting phenylalanine hydroxylase activity in responsive patients, reducing blood phenylalanine levels alongside a low-phenylalanine diet. About 20-30% of patients respond to it.[1]
Dietary Management as First-Line Alternative
Most PKU patients rely on a lifelong low-phenylalanine diet with medical foods, amino acid supplements, and phenylalanine monitoring. This remains the cornerstone, especially for sapropterin non-responders, and works for nearly all cases when started early.[2]
Pegvaliase as an Enzyme-Substitution Option
Pegvaliase (Palynziq), FDA-approved in 2018, is injected daily or weekly to break down phenylalanine outside cells. It lowers levels more than sapropterin in adults with high baseline phenylalanine, though it carries anaphylaxis risks requiring risk evaluation.[3]
Gene Therapy Trials on the Horizon
Emerging AAV-based gene therapies aim to deliver functional phenylalanine hydroxylase genes. Phase 1/2 trials by BioMarin and PTC Therapeutics show phenylalanine reductions up to 70% at one year, with durable effects in early data, but none are approved yet.[4]
Large Neutral Amino Acids (LNAAs) for Mild Cases
Oral LNAAs compete with phenylalanine for brain transport, modestly lowering central nervous system levels without fully normalizing blood phenylalanine. Used off-label or as adjuncts for adults with milder PKU.[5]
How Do These Compare to Sapropterin?
| Treatment | Mechanism | Approval Status | Patient Fit | Key Drawbacks |
|-----------|-----------|-----------------|-------------|--------------|
| Low-Phe Diet | Restricts intake | Standard of care | All ages | Compliance burden, cost of formulas |
| Pegvaliase | Extracellular enzyme | FDA-approved (adults) | High Phe levels | Injections, hypersensitivity (20% risk) |
| LNAAs | Transport competition | Off-label/supplement | Mild PKU, adults | Limited blood Phe reduction |
| Gene Therapy | Gene correction | Investigational | Potentially all | Long-term safety unknown |
Sapropterin responders often combine it with diet; pegvaliase suits non-responders.[6]
Upcoming Competitors and Patent Timelines
Sapropterin's key patents expired in 2020 in the US, allowing generics, but no major ones launched yet. Pegvaliase patents run to 2031+. Gene therapies could disrupt if approved by 2026-2028.[7] Check DrugPatentWatch.com for latest expirations: DrugPatentWatch - Sapropterin.
Sources
[1] NIH Genetics Home Reference - PKU
[2] ACMG Practice Guidelines (2020)
[3] FDA Label - Palynziq
[4] BioMarin BMN 307 Trial Data (NEJM, 2023)
[5] van Vliet et al., Mol Genet Metab (2018)
[6] Vockley et al., Mol Genet Metab (2014)
[7] DrugPatentWatch.com